Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea

Jie Hyun Kim, Kwang Hyub Han, Kwan Sik Lee, Young Nyun Park, Sang Hoon Ahn, Chae Yoon Chon, Young Myoung Moon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Combination therapy with interferon alpha (IFN-α) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%. The aim of this study was to investigate the long-term efficacy of combination therapy with IFN-α and ribavirin for chronic hepatitis C in Koreans. One hundred thirty-eight patients with chronic hepatitis C who received this combination therapy between 1995 and 2003 were analyzed retrospectively. All patients were treated with IFN-α 3-6 million units three times weekly in combination with 900-1200 mg/day of ribavirin for 24 weeks. The overall SVR rate was 41.3%. Patients were followed up for a median of 41 months (range, 12-105 months) after completion of therapy. In all of the SVR patients (57 patients), SVR was conserved during the follow-up period. None of the patients progressed to decompensated liver disease or hepatocellular carcinoma (HCC). However, 5 of the 81 non-SVR patients (6.2%) progressed to decompensated liver disease or HCC. In conclusion, combination therapy with IFN-α and ribavirin shows good long-term efficacy in patients with chronic hepatitis C in Korea, one of the highest endemic areas of hepatitis B virus (HBV) infection.

Original languageEnglish
Pages (from-to)793-798
Number of pages6
JournalYonsei medical journal
Volume47
Issue number6
DOIs
Publication statusPublished - 2006 Dec

Fingerprint

Ribavirin
Chronic Hepatitis C
Korea
Interferon-alpha
Therapeutics
Liver Diseases
Hepatocellular Carcinoma
Virus Diseases
Hepatitis B virus
Genotype

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{8107760e7afb420295f8bef0ad41d38a,
title = "Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea",
abstract = "Combination therapy with interferon alpha (IFN-α) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40{\%}. The aim of this study was to investigate the long-term efficacy of combination therapy with IFN-α and ribavirin for chronic hepatitis C in Koreans. One hundred thirty-eight patients with chronic hepatitis C who received this combination therapy between 1995 and 2003 were analyzed retrospectively. All patients were treated with IFN-α 3-6 million units three times weekly in combination with 900-1200 mg/day of ribavirin for 24 weeks. The overall SVR rate was 41.3{\%}. Patients were followed up for a median of 41 months (range, 12-105 months) after completion of therapy. In all of the SVR patients (57 patients), SVR was conserved during the follow-up period. None of the patients progressed to decompensated liver disease or hepatocellular carcinoma (HCC). However, 5 of the 81 non-SVR patients (6.2{\%}) progressed to decompensated liver disease or HCC. In conclusion, combination therapy with IFN-α and ribavirin shows good long-term efficacy in patients with chronic hepatitis C in Korea, one of the highest endemic areas of hepatitis B virus (HBV) infection.",
author = "Kim, {Jie Hyun} and Han, {Kwang Hyub} and Lee, {Kwan Sik} and Park, {Young Nyun} and Ahn, {Sang Hoon} and Chon, {Chae Yoon} and Moon, {Young Myoung}",
year = "2006",
month = "12",
doi = "10.3349/ymj.2006.47.6.793",
language = "English",
volume = "47",
pages = "793--798",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea. / Kim, Jie Hyun; Han, Kwang Hyub; Lee, Kwan Sik; Park, Young Nyun; Ahn, Sang Hoon; Chon, Chae Yoon; Moon, Young Myoung.

In: Yonsei medical journal, Vol. 47, No. 6, 12.2006, p. 793-798.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea

AU - Kim, Jie Hyun

AU - Han, Kwang Hyub

AU - Lee, Kwan Sik

AU - Park, Young Nyun

AU - Ahn, Sang Hoon

AU - Chon, Chae Yoon

AU - Moon, Young Myoung

PY - 2006/12

Y1 - 2006/12

N2 - Combination therapy with interferon alpha (IFN-α) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%. The aim of this study was to investigate the long-term efficacy of combination therapy with IFN-α and ribavirin for chronic hepatitis C in Koreans. One hundred thirty-eight patients with chronic hepatitis C who received this combination therapy between 1995 and 2003 were analyzed retrospectively. All patients were treated with IFN-α 3-6 million units three times weekly in combination with 900-1200 mg/day of ribavirin for 24 weeks. The overall SVR rate was 41.3%. Patients were followed up for a median of 41 months (range, 12-105 months) after completion of therapy. In all of the SVR patients (57 patients), SVR was conserved during the follow-up period. None of the patients progressed to decompensated liver disease or hepatocellular carcinoma (HCC). However, 5 of the 81 non-SVR patients (6.2%) progressed to decompensated liver disease or HCC. In conclusion, combination therapy with IFN-α and ribavirin shows good long-term efficacy in patients with chronic hepatitis C in Korea, one of the highest endemic areas of hepatitis B virus (HBV) infection.

AB - Combination therapy with interferon alpha (IFN-α) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%. The aim of this study was to investigate the long-term efficacy of combination therapy with IFN-α and ribavirin for chronic hepatitis C in Koreans. One hundred thirty-eight patients with chronic hepatitis C who received this combination therapy between 1995 and 2003 were analyzed retrospectively. All patients were treated with IFN-α 3-6 million units three times weekly in combination with 900-1200 mg/day of ribavirin for 24 weeks. The overall SVR rate was 41.3%. Patients were followed up for a median of 41 months (range, 12-105 months) after completion of therapy. In all of the SVR patients (57 patients), SVR was conserved during the follow-up period. None of the patients progressed to decompensated liver disease or hepatocellular carcinoma (HCC). However, 5 of the 81 non-SVR patients (6.2%) progressed to decompensated liver disease or HCC. In conclusion, combination therapy with IFN-α and ribavirin shows good long-term efficacy in patients with chronic hepatitis C in Korea, one of the highest endemic areas of hepatitis B virus (HBV) infection.

UR - http://www.scopus.com/inward/record.url?scp=33845927812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845927812&partnerID=8YFLogxK

U2 - 10.3349/ymj.2006.47.6.793

DO - 10.3349/ymj.2006.47.6.793

M3 - Article

C2 - 17191307

AN - SCOPUS:33845927812

VL - 47

SP - 793

EP - 798

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -